406 related articles for article (PubMed ID: 22506881)
1. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
Jain S; Shahane A; Derk CT
Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
[TBL] [Abstract][Full Text] [Related]
2. Progressive systemic sclerosis and the lung.
Veeraraghavan S; Sharma OP
Curr Opin Pulm Med; 1998 Sep; 4(5):305-9. PubMed ID: 10813207
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.
Tan A; Denton CP; Mikhailidis DP; Seifalian AM
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S66-74. PubMed ID: 21586221
[TBL] [Abstract][Full Text] [Related]
4. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
Fathi N; Furst DE; Clements PJ
Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
[TBL] [Abstract][Full Text] [Related]
5. [Systemic sclerosis].
Schinke S; Riemekasten G
Internist (Berl); 2019 Dec; 60(12):1251-1269. PubMed ID: 31754753
[TBL] [Abstract][Full Text] [Related]
6. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs and therapeutics for systemic sclerosis.
Lee JJ; Pope JE
Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease in systemic sclerosis: current and future treatment.
Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for systemic sclerosis.
Steen V
Autoimmun Rev; 2006 Feb; 5(2):122-4. PubMed ID: 16431341
[TBL] [Abstract][Full Text] [Related]
11. Coagulation and autoimmunity in scleroderma interstitial lung disease.
Ludwicka-Bradley A; Silver RM; Bogatkevich GS
Semin Arthritis Rheum; 2011 Oct; 41(2):212-22. PubMed ID: 21168185
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
Broad K; Pope JE
Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary complications: one of the most challenging complications of systemic sclerosis.
Wells AU; Steen V; Valentini G
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii40-4. PubMed ID: 19487223
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Volkmann ER; Tashkin DP
Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
[TBL] [Abstract][Full Text] [Related]
15. The evolving pharmacotherapy of pulmonary fibrosis.
Lota HK; Wells AU
Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Management of Systemic Sclerosis: A Practical Approach.
Lee JJ; Pope JE
Drugs; 2016 Feb; 76(2):203-13. PubMed ID: 26659258
[TBL] [Abstract][Full Text] [Related]
17. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
[TBL] [Abstract][Full Text] [Related]
18. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].
Buschulte K; Hoffmann-Vold AM; Dobrota RD; Höger P; Krause A; Kreuter M
Z Rheumatol; 2021 Oct; 80(8):743-754. PubMed ID: 34505934
[TBL] [Abstract][Full Text] [Related]
20. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
